Preprint Case Report Version 1 Preserved in Portico This version is not peer-reviewed

First Case Report of Sunvozertinib for the Treatment of Her2 Exon 20 Insertion in Lung Adenocarcinoma

Tao Luan
ORCID logo ,
Xin Qing Lin
,
Xiao Hong Xie
,
Shuai Yin Wang
,
Heng Lu
,
Lian sheng Liu
,
Gang Yang
,
Yun Hui Zhang
,
Cheng Zhi Zhou
*
Version 1 : Received: 12 January 2024 / Approved: 12 January 2024 / Online: 12 January 2024 (09:49:20 CET)

How to cite: Luan, T.; Lin, X.Q.; Xie, X.H.; Wang, S.Y.; Lu, H.; Liu, L.S.; Yang, G.; Zhang, Y.H.; Zhou, C.Z. First Case Report of Sunvozertinib for the Treatment of Her2 Exon 20 Insertion in Lung Adenocarcinoma. Preprints 2024, 2024011009. https://doi.org/10.20944/preprints202401.1009.v1 Luan, T.; Lin, X.Q.; Xie, X.H.; Wang, S.Y.; Lu, H.; Liu, L.S.; Yang, G.; Zhang, Y.H.; Zhou, C.Z. First Case Report of Sunvozertinib for the Treatment of Her2 Exon 20 Insertion in Lung Adenocarcinoma. Preprints 2024, 2024011009. https://doi.org/10.20944/preprints202401.1009.v1

Abstract

Human Epidermal Growth Factor Receptor 2(HER2) is a transmembrane glycoprotein receptor with intracellular tyrosine kinase activity. It is generally considered as a poor prognostic marker. Targeted therapies, such as small molecule tyrosine kinase inhibitors (TKIs), showed limited efficacy in HER2-mutant advanced Non-Small Cell Lung Cancer (NSCLC). In the 2023 NCCN guidelines for NSCLC, Antibody-Drug Conjugate(ADC) Trastuzumab emtansine (T-DM1) is recommended for the treatment of HER2-mutant Lung Cancer (LC). However, this medication is currently not approved in certain regions.So it is necessary to explore alternative treatment options for HER2-mutant NSCLC patients.In our study of a patient with HER2 exon 20ins Lung Adenocarcinoma who had previously failed multiple TKI treatments, we discovered that Sunvozertinib could stabilize the patient's condition, achieving a progression-free survival (PFS) of 87 days. This is a novel finding that may provide new treatment options for HER2 exon 20ins patients who have failed TKI therapy.

Keywords

case report; targeted therapy; gene mutation; novel therapy

Subject

Medicine and Pharmacology, Clinical Medicine

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.